This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy



Ziphius, founded in 2019, is a Belgian-based pharmaceutical company with a mission to reduce the global impact of infectious and rare genetic diseases. Through its innovative Platform Technology utilizing self-amplifying RNA (saRNA), the company develops safe and effective biopharmaceuticals, including prophylactic vaccines and gene supplementation therapies. Located in New York, USA and Merelbeke, Belgium Ziphius focuses on combining self-amplifying saRNA technologies with advanced lipid formulations for targeted delivery. Their primary emphasis lies in the preclinical and early clinical phases, addressing prophylactic vaccines and protein-enhancement therapies for rare genetic disorders. The Ziphius team consist of complementary highly dedicated experts with a strong entrepreneurial, scientific, clinical, managerial and pharmaceutical background